PDS Biotechnology Stock Gets Nasdaq Extension as Traders Eye PDSB
PDS Biotechnology Corporation shares traded higher after the cancer immunotherapy company said Nasdaq signed off on its compliance with the $1 minimum bid-price rule. That wraps up a deficiency issue that’s been on the stock since February. The minimum bid requirement says a listed stock has to stay over a certain price to keep its exchange listing. Nasdaq’s June 2 notice takes off the immediate delisting risk for PDSB, which had traded under $1 for 30 business days in a row earlier this year, according to a filing. The company still faces the same clinical and cash needs as before, but now without the near-term threat of a delisting process tied to that breach.